CervoMed announced plans to initiate a Phase III clinical trial in the second half of 2026 to evaluate the efficacy and safety of its candidate drug Neflamapimod in patients with dementia with Lewy bodies (DLB).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jefferies raises Tesla's target price to $400
Goldman Sachs (GS.US) stock plunges 22% into bear market, financial report becomes the key to a breakthrough
Goldman Sachs' market value evaporated by several billions, with its share price down more than 22% from the year's high. Despite Q3 revenue exceeding expectations, a 41% drop in M&A activity and a slowdown in IPOs have dampened market sentiment. Analysts project a 12% revenue increase in Q4, but technical indicators suggest there is further downside risk to $783. Rumors about management transitions have also drawn attention.
Delivery soared by 85% but failed to prevent the death cross; Rivian (RIVN.US) dilution risk sparks panic
Despite the R2 model driving an 85% year-on-year increase in deliveries, Rivian's stock price continues to decline due to technical death cross, high short interest, and risks of equity dilution, facing a severe market test.
Crypto prices
More
